PharmaFrontiers Acquires Autologous T Cell Vaccine Rights For Rheumatoid Arthritis

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jan. 17, 2006--PharmaFrontiers Corp. (OTCBB:PFTR), a company involved in the development and commercialization of cell therapies, announced today that it has acquired an exclusive worldwide license for the intellectual property rights and research results of an autologous T cell vaccine for rheumatoid arthritis from the Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences of the People's Republic of China. The U.S. Centers for Disease Control (CDC) estimates that more than two million adults in the U.S. have rheumatoid arthritis, an autoimmune disease. Spending in the U.S. on the treatment of rheumatoid arthritis is projected to grow to $9.5 billion annually by 2013, according to Decision Resources, an independent research firm focused on the pharmaceutical industry.